Intravitreal Anti-VEGF in Exudative AMD With Epiretinal Membranes

Age Related Macular Degeneration Clinical Trial

Official title:

Visual and Anatomic Outcomes of Intravitreal Anti-VEGF Therapy for Exudative Age-related Macular Degeneration With Concurrent Significant Epiretinal Membrane.

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01846351
• Other study ID #: NAC270608
• Status: Completed
• Phase: N/A
• First received: May 1, 2013
• Last updated: May 1, 2013
• Start date: July 2006
• Est. completion date: February 2010

Study information

• Verified date: May 2013
• Source: New England Retina Associates
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Institutional Review Board
• Study type: Observational

Clinical Trial Summary

Study designed to evaluate the effect of significant ERM on the visual and anatomic outcomes of intravitreal anti-VEGF therapy for eAMD.

Description:

Gass in 1987 described three cases of epiretinal membrane (ERM) associated with wet macular degeneration. Since then we have seen that is not rare to find the coexistence of these entities. An ERM may produce intrinsic disorganization of the outer retina leading to persistent increased macular thickness and/or edema. This persistent edema may affect the effectiveness in the treatment of exudative age-related macular degeneration (eAMD). Therefore, this study was designed to evaluate the effect of significant ERM on the visual and anatomic outcomes of intravitreal anti-VEGF therapy for eAMD.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 16
• Est. completion date: February 2010
• Est. primary completion date: February 2010
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 58 Years to 90 Years

Eligibility

Inclusion Criteria:

• Significant epiretinal membrane

• Anti-VEGF treatment for age-related macular degeneration

Exclusion Criteria:

• Uveitis

• Macular disorders

• Diabetic retinopathy

• Vascular occlusions

Study Design

Time Perspective: Retrospective

Related Conditions & MeSH terms

• Age Related Macular Degeneration
• Epiretinal Membrane
• Macular Degeneration

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
New England Retina Associates

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Best corrected visual acuity	Evaluate the best visual acuity during the follow up.	12 months	No
Primary	Central macular thickness	Evaluation of the retinal thickness changes with anti-VEGF treatment	12 months	No
Primary	Fluorescein angiogram	Evaluation of changes in lesion size during follow-up.	12 months	No